Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Conference contribution


Publication Details

Author(s): Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, Kulke M, Pavel ME, Yao JC
Publication year: 2018
Volume: 106
Pages range: 211-211
ISSN: 0028-3835


FAU Authors / FAU Editors

Pavel, Marianne Ellen
Professur für Endokrinologie


External institutions with authors

Dana–Farber Cancer Institute
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Fondazione IRCCS: Istituto Nazionale dei Tumori
H. Lee Moffitt Cancer Center & Research Institute
Istituto Clinico Humanitas
Novartis AG
Novartis Pharma S.A.S.
University of Manchester
University of Texas MD Anderson Cancer Center


How to cite

APA:
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Herbst, F., Ridolfi, A.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).

MLA:
Fazio, N., et al. "Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials." 2018. 211-211.

BibTeX: 

Last updated on 2019-29-08 at 07:10